Compare OPK & LMRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | LMRI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.2M | 753.7M |
| IPO Year | 2011 | N/A |
| Metric | OPK | LMRI |
|---|---|---|
| Price | $1.10 | $10.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $1.60 | ★ $20.75 |
| AVG Volume (30 Days) | ★ 2.2M | 698.1K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $606,879,000.00 | N/A |
| Revenue This Year | N/A | $6.35 |
| Revenue Next Year | $4.24 | $5.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $7.23 |
| 52 Week High | $1.60 | $19.45 |
| Indicator | OPK | LMRI |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 52.45 |
| Support Level | N/A | $9.97 |
| Resistance Level | $1.25 | $10.35 |
| Average True Range (ATR) | 0.05 | 0.59 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 48.78 | 89.54 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists' interpretations of those studies.